| 產品名稱 | C3A [HepG2/C3A, derivative of Hep G2 (ATCC HB-8065)] (ATCC® CRL-10741™) |
|---|---|
| 商品貨號 | B164087 |
| Organism | Homo sapiens, human |
| Tissue | liver |
| Product Format | frozen |
| Morphology | epithelial |
| Culture Properties | adherent |
| Biosafety Level | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease | hepatocellular carcinoma |
| Age | 15 years adolescent |
| Gender | male |
| Ethnicity | Caucasian |
| Applications | This cell line is a suitable transfection host. |
| Storage Conditions | liquid nitrogen vapor phase |
| Disclosure | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Images |  |
| Derivation | C3A is clonal derivative of Hep G2 that was selected for strong contact inhibition of growth, high albumin production, high production of alpha fetoprotein (AFP) and ability to grow in glucose deficient medium. |
| Clinical Data | 15 years adolescent Caucasian male |
| Genes Expressed | alpha-fetoprotein (alpha fetoprotein); albumin; alpha2 macroglobulin (alpha-2-macroglobulin); alpha1 antitrypsin (alpha-1-antitrypsin); transferrin; alpha1 antichymotrypsin; (alpha-1-antichymotrypsin); haptoglobin; ceruloplasmin; plasminogen;,complement (C4); C3 activator; fibrinogen; alpha1 acid glycoprotein (alpha-1 acid glycoprotein); alpha2 HS glycoprotein (alpha-2-HS-glycoprotein); beta lipoprotein (beta-lipoprotein); retinol binding protein (retinol-binding protein) |
| Cellular Products | alpha-fetoprotein (alpha fetoprotein); albumin; alpha2 macroglobulin (alpha-2-macroglobulin); alpha1 antitrypsin (alpha-1-antitrypsin); transferrin; alpha1 antichymotrypsin; (alpha-1-antichymotrypsin); haptoglobin; ceruloplasmin; plasminogen; complement (C4); C3 activator; fibrinogen; alpha1 acid glycoprotein (alpha-1 acid glycoprotein); alpha2 HS glycoprotein (alpha-2-HS-glycoprotein); beta lipoprotein (beta-lipoprotein); retinol binding protein (retinol-binding protein) |
| Tumorigenic | No |
| Effects | No, in immunosuppressed mice Yes, in semisolid medium |
| Comments | As the cells become confluent, there is a marked reduction in AFP secretion and an increase in albumin secretion. Gluconeogenesis activity is strongly oxgen dependent. The cells have nitrogen metabolizing activity comparable to perfused rat livers. There is no evidence of a Hepatitis B virus genome in this cell line. |
| Complete Growth Medium | The base medium for this cell line is ATCC-formulated Eagle's Minimum Essential Medium, Catalog No. 30-2003. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
| Subculturing | Volumes are given for a 75 cm2 flask. Increase or decrease the amount of dissociation medium needed proportionally for culture vessels of other sizes.
Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:6 is recommended Medium Renewal: Twice per week |
| Cryopreservation | Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions | Temperature: 37°C |
| STR Profile | Amelogenin: X,Y CSF1PO: 10,11 D13S317: 9,13 D16S539: 12,13 D5S818: 11,13 D7S820: 10 THO1: 9 TPOX: 8,9 vWA: 17 |
| Name of Depositor | Baylor College of Medicine |
| Deposited As | Homo sapiens |
| U.S. Patent Number | |
| References | Kelly JH. Permanent human hepatocyte cell line and its use in a liver assist device (LAD). US Patent 5,290,684 dated Mar 1 1994 |
| 梅經理 | 17280875617 | 1438578920 |
| 胡經理 | 13345964880 | 2438244627 |
| 周經理 | 17757487661 | 1296385441 |
| 于經理 | 18067160830 | 2088210172 |
| 沈經理 | 19548299266 | 2662369050 |
| 李經理 | 13626845108 | 972239479 |
